Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (3544)	1/6/1998 11:20:00 AM
From: Izzy	Read Replies (2) \| Respond to of 6136

Peter, I'll let JLL (or any other M.D.) give his perspective. I will give you my initial thoughts without trying to write a thesis. There are many factors: 1) Doctor's training, experience, and HIV interest, 2) Patient cooperation (eg., avoidance of continued drug abuse, etc.), compliance, 3) Availability, cost of medications, 4) Progress, results of clinical trials of old/new anti-HIV therapies, 4) Policies of federal, state health plans; guidelines of HMOs, "Managed Care Organizations", 5) FDA drug approvals, 6) Lack of a recognized HIV specialty, 7) Miscellaneous. The most important and crucial factor is a well-informed patient. If needed, I will add additional input after the others have replied. From a personal standpoint, I have been a doctor for 30+ yrs, 8 yrs post-graduate training (after medical school), treatment of HIV patients since 1985, medical director of the 4th largest publicly owned HMO (1980s), board certified, and continued interest in HIV (I'm not trying to be self-aggrandizing but just trying to point out the differences in doctor qualifications; patients should check the credentials of their doctors, IMO). Enough said for now. Didn't mean to belabor the point but have been trying to give you honest answers to your excellent questions.